Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 3/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.41 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26154173 | 0.84 | OPRM1 (0.47) | OPRM1BRD4JAK2MAP2K4MAP2K7 | |
| SCHEMBL22609010 | 0.80 | JAK3 (0.41) | JAK3DRD2DRD3ALOX12HTR2C | |
| SCHEMBL25098486 | 0.78 | OPRM1 (0.44) | OPRM1BRD4MAP2K4MAP2K7 | |
| SCHEMBL20632836 | 0.77 | HTR2C (0.50) | JAK3DRD2DRD3HTR2C | |
| SCHEMBL16834995 | 0.76 | HTR2C (0.54) | OPRM1JAK3ALOX12HTR2C | |
| SCHEMBL1546191 | 0.76 | ALOX12 (0.50) | DRD2DRD3ALOX12 | |
| SCHEMBL4195766 | 0.75 | HTR2C (0.53) | HTR2C | |
| SCHEMBL4206291 | 0.75 | HTR2C (0.53) | HTR2C | |
| SCHEMBL4195759 | 0.75 | HTR2C (0.53) | HTR2C | |
| Hydrochloric Acid SCHEMBL16835133 | 0.75 | HTR2C (0.55) | OPRM1JAK3ALOX12HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109956931-B | Tetrahydropyrrole compound, preparation method thereof, pharmaceutical composition and application thereof | 迈第康(上海)生物医药科技有限公司 | 2021-07-16 | — | — | CN | disclosed |
| US-20210024498-A1 | TETRAHYDROPYRROLE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | MEDICONNS SHANGHAI BIOPHARMACEUTICAL CO LTD (CN) | 2021-01-28 | — | — | US | disclosed |
| US-20210024498-A1 | TETRAHYDROPYRROLE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | MEDICONNS SHANGHAI BIOPHARMACEUTICAL CO LTD (CN) | 2021-01-28 | — | — | US | disclosed |
| EP-3733670-A1 | TETRAHYDROPYRROLE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | Mediconns (Shanghai) Biopharmaceutical Co., Ltd (CN) | 2020-11-04 | — | — | EP | disclosed |
| EP-3733670-A1 | TETRAHYDROPYRROLE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | Mediconns (Shanghai) Biopharmaceutical Co., Ltd (CN) | 2020-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024498-A1 | TETRAHYDROPYRROLE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | PRLHR, DRD2, AVPR2 | OPRM1 296/4885JAK3 2191/4885BRD4 2317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.